Lakefront Biotherapeutics (LKFT) Q1 2026 earnings review
A €3 Billion Shell No More: The Ouro Era Begins
Galapagos—now rebranding as Lakefront Biotherapeutics—is officially executing its pivot. Legacy revenue essentially evaporated this quarter (down 91% YoY) as the deferred income from the old Gilead platform deal ran dry. The real story, however, is capital deployment. The company is using its massive cash pile to fund half of Gilead's $1.675B acquisition of Ouro Medicines. This brings gamgertamig (OM336), a highly promising T cell engager for autoimmune diseases, into the pipeline. While Q1 printed a €14.5M net profit, it was entirely driven by €64.3M in FX and fair value gains on its USD-heavy cash reserves. Operating losses remain steep at €63.7M. Consequently, cash levels, which had been stable around €3B, are reversing direction and will plummet to roughly €2B by year-end as the Ouro upfront payment and legacy cell therapy wind-down costs hit the balance sheet.
🐂 Bull Case
Gamgertamig (OM336) has Fast Track and Orphan Drug Designation for severe autoimmune diseases (AIHA, ITP). Acquiring an operating business with a clear, near-term path to registrational studies (2027) gives the company a much-needed new identity.
The Ouro deal amends the restrictive Gilead collaboration, designating $500M of Galapagos' cash for R&D or independent strategic transactions. Crucially, up to $150M of this can be used for share repurchases, providing a direct lever to close the stock's discount to cash.
🐻 Bear Case
The company's €3B safety net is shrinking fast. The Ouro deal requires an $837.5M upfront payment plus €60-€75M in 2026 operating/transaction expenses. Add €125-€175M in cell therapy wind-down costs, and the year-end cash balance will compress by roughly a third.
With the Gilead discovery platform deferred revenue fully recognized in late 2025, total net revenues plummeted 91% YoY to just €6.5M. The company is effectively pre-revenue again, relying entirely on clinical execution and its balance sheet.
⚖️ Verdict: ⚪
Neutral. The company successfully executed the exact type of BD deal it promised, bringing in a high-potential autoimmune asset. However, the price tag is staggering, and the transition from a cash-rich holding company back to a cash-burning biotech carries substantial execution risk.
Key Themes
The Gamgertamig (OM336) Growth Engine
The Ouro acquisition brings gamgertamig (OM336), a BCMAxCD3 T cell engager, into the portfolio. By redirecting T cells toward BCMA-expressing plasma cells, it offers a precision approach to B cell depletion in autoimmune conditions. With transformative efficacy seen in Phase 1/2 for AIHA and ITP, and registrational trials expected by 2027, this specific technology represents the company's new primary growth driver.
Renegotiated Gilead Agreement Frees Up Capital
A crucial secondary benefit of the Ouro transaction is the amendment of the legacy Gilead Option, License, and Collaboration Agreement. It frees up $500M for independent business development, of which $150M is earmarked for potential share repurchases. This restores financial agility and gives management a tool to combat the stock's persistent discount to net asset value.
R&D Cost Base Drastically Reset
The brutal restructuring of 2025 is showing in the P&L. R&D expenses decelerated massively, falling 83% YoY from €182.7M in 25Q1 to just €31.0M in 26Q1. This lean cost structure is essential before the company takes on Ouro's development costs (which Galapagos must fund entirely through the initiation of registrational trials).
Cell Therapy Wind-Down Still Bleeding Cash
Despite the forward-looking BD narrative, the ghost of the cell therapy division remains. The company reaffirmed that the wind-down will only be substantially complete by Q3 2026, costing another €125M to €175M in cash this year. This drag contradicts the narrative of a clean, swift slate.
Macro: Heavy Dependency on USD/EUR FX Rates
With the company transitioning to a US-centric BD strategy, it holds $2.55B in USD (up from $2.16B at year-end 2025). This heavy concentration creates immense volatility below the operating line. Q1 2026 printed a net profit solely because of €23.8M in unrealized currency exchange gains and €40.0M in positive fair value changes. A weakening dollar would reverse these gains instantly.
Legacy TYK2 Asset (GLPG3667) Still in Limbo
While management acted decisively on Ouro, the legacy GLPG3667 program remains unresolved. The company is 'evaluating all strategic options' while waiting for final Week 48 GALACELA SLE data in Q2 2026. This prolonged uncertainty ties up internal focus and highlights an inability to swiftly monetize older assets.
Corporate Rebranding to Lakefront Biotherapeutics
Approved at the EGM, the name change to Lakefront Biotherapeutics (ticker: LKFT) officially severs ties with the Galapagos legacy. Along with Gino Santini taking over as Chair of the Board, it visually and structurally cements the 'SpinCo' pivot initiated by CEO Henry Gosebruch over the last year.
Other KPIs
Reversing. Down 97% YoY from €61.2M. The deferred income related to the Gilead drug discovery platform was fully released in 2025. Moving forward, the company has virtually no recurring collaboration revenue until new partnerships yield milestones or royalties.
Decelerating. Down 64% YoY from €13.8M. This relates entirely to the legacy supply of Jyseleca to Alfasigma under a transition agreement, a low-margin operation (Cost of Sales was €4.8M, yielding a gross profit of practically zero).
Accelerating. Up from just €2.4M a year ago. Driven by €12.9M in pure interest income and €64.3M in fair value/FX adjustments. This is currently the company's only source of profitability, masking a €63.7M operating loss.
Guidance
Decelerating. Management slashed this estimate from their previous Q4 2025 guidance of €2.775B - €2.850B. The roughly €800M downward revision directly reflects the aggressive deployment of capital for the Ouro acquisition and the consequent reduction in future interest income.
Accelerating capital deployment. This includes the $837.5M upfront payment to Gilead, plus one-time transaction and operating costs for integrating the ~20 Ouro employees, assuming a mid-year close.
Stable. The company maintained its previous guidance for these one-time cash costs. The wind-down is expected to be substantially complete by the end of Q3 2026.
Key Questions
Ouro Integration Timeline
You are absorbing roughly 20 Ouro employees and inheriting ongoing Phase 1/2 trials. Given the extensive restructuring of the past year, how prepared is the current R&D infrastructure to seamlessly transition Gamgertamig into registrational trials by 2027?
Share Repurchase Execution
With the new $150M authorization for share repurchases freed up from the Gilead agreement, how aggressive will you be in deploying this capital in the near term, given the stock's persistent discount to your €2B projected year-end cash balance?
KeyMed Milestone Visibility
Galapagos is responsible for 25% of the up to $610M in milestones owed to KeyMed for Gamgertamig. How are these milestones weighted (clinical vs. commercial), and what specific cash outflow should we model for this over the next 24-36 months?
GLPG3667 Monetization
With final Week 48 data for GLPG3667 in SLE expected in Q2 2026, will you require a partnership or divestiture immediately upon readout, or are you willing to fund any further advancement yourselves given the new autoimmune focus brought by Ouro?